Senaparib (IMP4297)

Senaparib (IMP4297; the registry's spelling of the code is IMP4927) is a small-molecule PARP inhibitor developed by IMPACT Therapeutics. The phase 3 study NCT04169997 (FLAMES, 404 participants) tested it as monotherapy maintenance after first-line chemotherapy in advanced ovarian cancer. On 17 September 2026 the CHMP adopted a positive opinion recommending a marketing authorisation for Sepalna (applicant SFL Pharmaceuticals Deutschland GmbH) as monotherapy for the maintenance treatment of adults with advanced (FIGO stage III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response after first-line platinum-based chemotherapy. The register gives the benefit as longer progression-free survival than placebo and lists anaemia, leukopenia, neutropenia, thrombocytopenia, nausea, raised transaminases and fatigue first among the most common side effects. The status stays at phase 3 until the European Commission decides. No efficacy figures are recorded here.